Biora Therapeutics Inc (BIOR)vsVertex Pharmaceuticals Inc (VRTX)
BIOR
Biora Therapeutics Inc
$0.22
0.00%
HEALTHCARE · Cap: $994,990
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1395400% more annual revenue ($12.00B vs $860,000). VRTX leads profitability with a 32.9% profit margin vs 0.0%. BIOR trades at a lower P/E of 0.6x. VRTX earns a higher WallStSmart Score of 66/100 (B-).
BIOR
Hold38
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+91.0%
Fair Value
$2.45
Current Price
$0.22
$2.23 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Revenue surging 158.0% year-over-year
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BIOR
The strongest argument for BIOR centers on P/E Ratio, Revenue Growth. Revenue growth of 158.0% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : BIOR
The primary concerns for BIOR are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BIOR profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
BIOR carries more volatility with a beta of 1.28 — expect wider price swings.
BIOR is growing revenue faster at 158.0% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 38/100), backed by strong 32.9% margins. BIOR offers better value entry with a 91.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Biora Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Biora Therapeutics, Inc., a biotechnology company, is engaged in the development of oral biotherapeutic products. The company is headquartered in San Diego, California.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?